The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX Cosmetic to treat masseter muscle prominence, the first neurotoxin indication for this specific aesthetic concern. The acceptance signals FDA agreement that the data package supports review, moving the indication toward a potential approval decision.
Regulatory
FDA Accepts BOTOX Cosmetic sBLA for Masseter Prominence
AbbVie's BOTOX Cosmetic wins FDA acceptance for masseter muscle prominence—first and only neurotoxin indication if approved.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
First neurotoxin indication for masseter prominence; exclusive if approved.
Masseter prominence—often called "square jaw" or mandibular hypertrophy—is a growing aesthetic category, particularly among younger patients seeking jawline refinement without surgery. If approved, BOTOX Cosmetic will own this indication exclusively among toxins. For practices, this represents a new revenue stream and a competitive advantage for AbbVie in the toxin portfolio. Expect marketing support and potential Allē rebate incentives tied to this indication once approved. Practices should begin training staff on patient selection and injection technique now.
Source: original report ↗
Frequently asked questions
What is masseter prominence and why do patients want it treated?
Masseter prominence, also called 'square jaw' or mandibular hypertrophy, is enlargement of the masseter muscle that creates a wider or more angular jawline. Younger patients increasingly seek this treatment for jawline refinement without undergoing surgery.
Will BOTOX Cosmetic be the only neurotoxin approved for masseter prominence?
Yes, if approved, BOTOX Cosmetic will be the first and only neurotoxin indication for masseter muscle prominence, giving AbbVie exclusive market ownership of this aesthetic category among toxins.
What does FDA acceptance of the sBLA mean for BOTOX Cosmetic?
FDA acceptance means the agency has determined AbbVie's data package is sufficient to support a formal review. This moves the indication toward a potential approval decision, though final approval is not yet guaranteed.
When will BOTOX Cosmetic be approved for masseter prominence?
The FDA has accepted the application for review, but no approval date has been announced. Practices should monitor AbbVie communications and FDA announcements for the approval timeline.
What should medspa practices do to prepare for this new BOTOX indication?
Begin training staff now on patient selection criteria and proper injection technique for masseter treatment. Expect marketing support and potential Allē rebate incentives from AbbVie once the indication is approved, which will create a new revenue stream and competitive advantage.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.